Blood Clot Risks For Yasmin, Yaz, Ortho Evra Get Panel Review After FDA Epidemiology Study
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Reproductive Health Drugs and Drug Safety and Risk Management advisory committees will discuss the benefits and risks of drospirenone-containing drugs and the Ortho Evra patch at a two-day meeting in December.